Healthcare
Technology
Health

Horizon Therapeutics

$27.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.22 (0.80%) As of 2:29 PM EDT today
+$0.22 (0.80%) Today

Why Robinhood?

You can buy or sell HZNP and other stocks, options, ETFs, and crypto commission-free!

About HZNP

Horizon Therapeutics Public Limited Company Ordinary Shares, also called Horizon Therapeutics, is a biopharmaceutical company which is engaged in the research, development and market of pharmaceutical products. The medicines intend to treat arthritis, inflammation and orphan diseases. Read More It distributes its products under the brands such as Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid, Ravicti, Rayos and Vimovo. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Employees
1,000
Headquarters
Dublin, Dublin
Founded
2008
Market Cap
5.13B
Price-Earnings Ratio
63.13
Dividend Yield
0.00
Average Volume
1.82M
High Today
$27.93
Low Today
$27.40
Open Price
$27.50
Volume
584.05K
52 Week High
$29.44
52 Week Low
$16.56

Collections

Healthcare
Technology
Health
Pharmaceutical
Therapy
Biopharmaceutical
Europe (Non-UK)
Europe

HZNP News

BenzingaAug 14

Horizon Therapeutics Has 'Headroom For Value Creation,' BMO Says In Upgrade

33

HZNP Earnings

$0.03
$0.24
$0.46
$0.67
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
$0.37 per share
Actual
$0.49 per share

More HZNP News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.